Lantern Pharma Receives Three FDA Rare Pediatric Disease Designations For LP-184 In Malignant Rhabdoid Tumors, Rhabdomyosarcoma, And Hepatoblastoma, Bringing Total To Four RPDDs
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma has received three FDA Rare Pediatric Disease Designations for its drug LP-184, targeting malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma. This brings the total to four RPDDs for the company.
September 23, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantern Pharma has been granted three additional FDA Rare Pediatric Disease Designations for its drug LP-184, which could enhance its market potential and investor interest.
The FDA designations are significant as they can lead to priority review vouchers, enhancing the drug's market potential. This news is likely to positively impact Lantern Pharma's stock price in the short term due to increased investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100